Published in J Am Heart Assoc on April 01, 2017
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet (1994) 40.72
Marginal structural models and causal inference in epidemiology. Epidemiology (2000) 33.54
Estimating causal effects from large data sets using propensity scores. Ann Intern Med (1997) 19.65
A structural approach to selection bias. Epidemiology (2004) 16.44
Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology (2000) 15.40
The natural history of congestive heart failure: the Framingham study. N Engl J Med (1971) 13.94
An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies. Multivariate Behav Res (2011) 13.63
Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med (2004) 12.52
Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol (2003) 11.24
Rosuvastatin in older patients with systolic heart failure. N Engl J Med (2007) 7.55
Racial differences in incident heart failure among young adults. N Engl J Med (2009) 5.60
Lesser response to angiotensin-converting-enzyme inhibitor therapy in black as compared with white patients with left ventricular dysfunction. N Engl J Med (2001) 5.30
Epidemiology and risk profile of heart failure. Nat Rev Cardiol (2010) 4.88
Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol (2008) 4.83
Why are African Americans under-represented in medical research studies? Impediments to participation. Ethn Health (1997) 4.63
Estimating the causal effect of zidovudine on CD4 count with a marginal structural model for repeated measures. Stat Med (2002) 4.15
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet (2008) 4.10
Racial differences in the outcome of left ventricular dysfunction. N Engl J Med (1999) 3.85
Differences in the incidence of congestive heart failure by ethnicity: the multi-ethnic study of atherosclerosis. Arch Intern Med (2008) 3.76
Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med (2001) 3.44
Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). J Am Coll Cardiol (2009) 3.32
Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA (2006) 3.20
Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol (1997) 3.02
Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure. Am J Cardiol (2009) 2.21
Racial differences in response to therapy for heart failure: analysis of the vasodilator-heart failure trials. Vasodilator-Heart Failure Trial Study Group. J Card Fail (1999) 1.96
Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Eur Heart J (2012) 1.93
The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. Eur Heart J (2015) 1.83
Epidemiology of heart failure in sub-Saharan Africa. Expert Rev Cardiovasc Ther (2009) 1.59
Association of β-blocker exposure with outcomes in heart failure differs between African American and white patients. Circ Heart Fail (2012) 1.55
Usefulness of atorvastatin in patients with heart failure due to inflammatory dilated cardiomyopathy and elevated cholesterol levels. Am J Cardiol (2006) 1.55
Impact of statin use on heart failure mortality. Int J Cardiol (2010) 1.48
African-American Heart Failure Trial (A-HeFT): rationale, design, and methodology. J Card Fail (2002) 1.11
Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation (2007) 1.10
Heart failure care in low- and middle-income countries: a systematic review and meta-analysis. PLoS Med (2014) 1.06
Intermolecular differences of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors contribute to distinct pharmacologic and pleiotropic actions. Am J Cardiol (2005) 1.03
Limitation of inverse probability-of-censoring weights in estimating survival in the presence of strong selection bias. Am J Epidemiol (2011) 1.02
Atorvastatin therapy may reduce the incidence of sudden cardiac death in patients with advanced chronic heart failure. J Card Fail (2008) 0.94
Statin use and survival in patients with chronic heart failure--results from two observational studies with 5200 patients. Int J Cardiol (2006) 0.90
Statin therapy is associated with improved cardiovascular outcomes and levels of inflammatory markers in patients with heart failure. J Card Fail (2005) 0.89
Statins in heart failure: do we need another trial? Vasc Health Risk Manag (2013) 0.88
Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study. Am Heart J (2007) 0.87
Evaluating health management programmes over time: application of propensity score-based weighting to longitudinal data. J Eval Clin Pract (2010) 0.85
Association between use of statins and outcomes in heart failure with reduced ejection fraction: prospective propensity score matched cohort study of 21 864 patients in the Swedish Heart Failure Registry. Circ Heart Fail (2015) 0.85
Statins in heart failure: the paradox between large randomized clinical trials and real life. Mayo Clin Proc (2012) 0.85
Efficacy of statin therapy in chronic systolic cardiac insufficiency: a meta-analysis. Eur J Intern Med (2011) 0.83
Statins and heart failure. J Am Coll Cardiol (2010) 0.82
Drug insight: statins for nonischemic heart failure--evidence and potential mechanisms. Nat Clin Pract Cardiovasc Med (2007) 0.82
Effects of Statin Treatment on Inflammation and Cardiac Function in Heart Failure: An Adjusted Indirect Comparison Meta-Analysis of Randomized Trials. Cardiovasc Ther (2015) 0.82
The performance of inverse probability of treatment weighting and full matching on the propensity score in the presence of model misspecification when estimating the effect of treatment on survival outcomes. Stat Methods Med Res (2015) 0.81
Relationship between recommended chronic heart failure treatments and mortality over 8 years in real-world conditions: a pharmacoepidemiological study. Eur J Clin Pharmacol (2012) 0.81
Statin therapy and clinical outcomes in heart failure: a propensity-matched analysis. J Card Fail (2008) 0.80
Comparing a marginal structural model with a Cox proportional hazard model to estimate the effect of time-dependent drug use in observational studies: statin use for primary prevention of cardiovascular disease as an example from the Rotterdam Study. Eur J Epidemiol (2014) 0.78
Can natriuretic peptides help identify heart failure patients for whom statins are beneficial? J Am Coll Cardiol (2009) 0.78
Use of Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Risk of Dementia in Heart Failure. Am J Alzheimers Dis Other Demen (2015) 0.78
Lipophilic Statin Versus Rosuvastatin (Hydrophilic) Treatment for Heart Failure: a Meta-Analysis and Adjusted Indirect Comparison of Randomised Trials. Cardiovasc Drugs Ther (2016) 0.76
Lipophilicity and cardiovascular outcome in patients with CHF. Am Heart J (2008) 0.75